151 related articles for article (PubMed ID: 20329807)
1. Histrelin: in advanced prostate cancer.
Deeks ED
Drugs; 2010 Mar; 70(5):623-30. PubMed ID: 20329807
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
Schlegel PN;
J Urol; 2006 Apr; 175(4):1353-8. PubMed ID: 16515997
[TBL] [Abstract][Full Text] [Related]
3. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
4. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.
Schlegel PN; Kuzma P; Frick J; Farkas A; Gomahr A; Spitz I; Chertin B; Mack D; Jungwirth A; King P; Nash H; Bardin CW; Moo-Young A
Urology; 2001 Oct; 58(4):578-82. PubMed ID: 11597543
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer.
Shore N; Cookson MS; Gittelman MC
BJU Int; 2012 Jan; 109(2):226-32. PubMed ID: 21851539
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer.
Dineen MK; Tierney DS; Kuzma P; Pentikis HS
J Clin Pharmacol; 2005 Nov; 45(11):1245-9. PubMed ID: 16239357
[TBL] [Abstract][Full Text] [Related]
7. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
[TBL] [Abstract][Full Text] [Related]
8. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.
Schlegel P
BJU Int; 2009 Mar; 103 Suppl 2():7-13. PubMed ID: 19228147
[No Abstract] [Full Text] [Related]
9. A review of the use of histrelin acetate in the treatment of prostate cancer.
Crawford ED
BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
[TBL] [Abstract][Full Text] [Related]
11. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
12. Reversibility of androgen deprivation therapy in patients with prostate cancer.
Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer.
Fowler JE; Gottesman JE; Reid CF; Andriole GL; Soloway MS
J Urol; 2000 Sep; 164(3 Pt 1):730-4. PubMed ID: 10953135
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced liver injury caused by the histrelin (Vantus) subcutaneous implant.
Ricker JM; Foody WF; Shumway NM; Shaw JC
South Med J; 2010 Jan; 103(1):84-6. PubMed ID: 19996852
[TBL] [Abstract][Full Text] [Related]
16. [Histrelin acetate--the first once yearly LHRH agonist].
Altarac S
Lijec Vjesn; 2011; 133(9-10):320-2. PubMed ID: 22165080
[TBL] [Abstract][Full Text] [Related]
17. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
Pedraza R; Kwart AM
Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
[TBL] [Abstract][Full Text] [Related]
18. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
[TBL] [Abstract][Full Text] [Related]
19. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.
Raddin RS; Walko CM; Whang YE
Anticancer Drugs; 2011 Mar; 22(3):299-302. PubMed ID: 21360851
[TBL] [Abstract][Full Text] [Related]
20. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
Oefelein MG; Cornum R
J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]